Abstract: There is described a cellular behaviour monitoring device for monitoring changes in behaviour of cells contained in a sample. The device generally has a well plate with a sample receiving well recessed therein. A filter membrane extends across the well plate and hermetically covers the sample receiving well. The filter membrane has nutrient-permeable and cell-impermeable pores extending through the filter membrane. The device has an electrode layer extending across the filter membrane. The electrode layer has a substrate and behaviour monitoring electrodes spaced-apart from one another in a region of the substrate, with the region being aligned with the sample receiving well. The electrode layer has nutrient-permeable apertures distributed across the region, with at least some of pores are aligned with at least some of the apertures to allow fluid communication therebetween, and nutrient exchange between the sample receiving well and a surrounding environment.

Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.

Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Abstract: A radiation dosimeter for measuring radiation dose within a region includes a structure having a scintillating material that emits light when exposed to radiation. Deformable radio-luminescent elements are located within the structure and configured to generate optical energy in response to irradiation.

Abstract: There is provided herein thermoset porous polymer composites a methods for producing such composites. The method comprises: preparing a mixture comprising a resin, optionally a curing agent, and dry ice; optionally casting the mixture; curing the mixture to obtain the porous composite; and optionally controlling at least one of a reaction rate and an expansion rate of the mixture during the curing.

Abstract: The invention concerns a nutritional or therapeutic agent comprising a molecule mix obtained from Vitis vinifera and Vaccinium angustifolium, comprising: at least 1% of catechins and epicatechins, the percentage being given by weight in relation to the total weight of the mix, preferably at least 5%, at least 5 ppm (parts per million in the mix) of ferulic acid, preferably at least 10 ppm. The invention also relates to the use of this agent due to its effects on cognitive functions in particular.

Abstract: Methods for the diagnosis, prognosis, patient stratification and prediction of pharmacological response in patients afflicted by psychiatric disorders based on electroretinography (ERG) parameters are described.

Abstract: A jointed mechanism includes a passive pendulum system attached to and suspended from the multi-axis robot. The system includes one or more position sensors configured to measure a joint angle on the pendulum system, at least one arm, and an end-effector attached to a distal end of the pendulum system. A controller implements a method to selectively control motion of the robot in a plurality of control modes. The control modes include a Cooperative Mode and an Autonomous Mode. The controller is configured to detect contact with the end-effector when operating in the Autonomous Mode, and to automatically initiate a control action in response to the contact. The pendulum system may be a parallelogram arrangement.

Abstract: A shotcrete nozzle assembly comprising: a tubular body operatively connectable to a concrete source, the tubular body including a stream controlling section for controlling a stream of fresh concrete projected from an outlet body end, the stream controlling section including at least one helicoidal conduit defined within the body sidewall, each helicoidal conduit extending helicoidally around a central conduit between an air inlet end operatively connectable to a pressurized air source and an air outlet end located towards the outlet body end, each helicoidal conduit being twisted around the central passageway to guide pressurized air exiting through the air outlet end along an helicoidal path extending away from the outlet body end and around the stream of fresh concrete exiting the outlet body end.

Abstract: A shotcrete nozzle assembly comprising: a tubular body including a body sidewall defining a central passageway extending along a central longitudinal passageway axis, and water dispensing bores extending through the body sidewall and including: first and second sets of water dispensing bores positioned such that outlet openings thereof defined in an inner face of the body sidewall are disposed in a respective one of longitudinally spaced-apart first and second transversal planes extending perpendicularly to the passageway axis, at least some of the water dispensing bores being oriented such that the central bore axes thereof extend in a non-radial direction relative to the passageway axis, and such that an orthogonal projection of the central bore axes of the first and second sets of water dispensing bores onto one of the transversal planes forms first and second projected central bore axes which intersect each other at a first non-zero angle.

Abstract: There is provided herein thermoset porous polymer composites a methods for producing such composites. The method comprises: preparing a mixture comprising a resin, optionally a curing agent, and dry ice; optionally casting the mixture; curing the mixture to obtain the porous composite; and optionally controlling at least one of a reaction rate and an expansion rate of the mixture during the curing.

Abstract: Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display cytotoxicity on a variety of cancer cell lines. A process for producing the compounds and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: An insertion system includes an insertion device including a body defining a longitudinal axis, the body including a wall having an outer surface and an inner surface defining a cylindrical opening through the body, the body having a first body portion and a second body portion formed by separating the body along the longitudinal axis, an effector configured to interface with the insertion device, the effector having an effector body, a first mechanism coupled to the effector body and coupled to the first body portion of the insertion device, and a second mechanism coupled to the effector body and coupled to the second body portion of the insertion device, and an insertion mechanism coupled with the effector body. The insertion mechanism enables a force application at a position offset from the insertion device.

Abstract: A fluidic centripetal apparatus for testing components of a biological material in a fluid is presented. The fluidic centripetal device is adapted to be received within a rotatable holder. The apparatus comprises a fluidic component layer having fluidic features on at least a front face and a bottom component layer bonded to a rear of the fluidic component layer thereby creating a fluidic network through which the fluid flows under centripetal force. In one embodiment, the fluidic feature may be a bottom-Tillable chamber coupled to an entry channel for receiving the fluid, the chamber inlet being provided at an outer side of the bottom-fillable chamber.

Abstract: Colchicine derivative(s), method(s) and use(s) thereof for treatment of inflammation.

Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.

Abstract: A light-inducible intracellular protein aggregation system is described herein, which provides invaluable tools to study the role of protein aggregates in proteinopathies and to screen for novel therapeutic compounds. The system generally comprises a cell expressing an alpha-synuclein polypeptide or another proteopathic polypeptide that self-aggregates under pathogenic conditions, operably linked to a photoactivatable polypeptide. Illumination of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible accumulation of intracellular protein aggregates comprising the alpha-synuclein polypeptide or proteopathic polypeptide. The intracellular protein aggregates can be made to accumulate in real-time during the illumination, thereby enabling spatiotemporal control of protein aggregation.

Abstract: A parallel mechanism comprises legs with kinematically redundant actuation for a parallel mechanism. Each of these legs comprises a first sub-leg and a second sub-leg each with a proximal end and a distal end. A link has a proximal end and a distal end. A joint with a rotational degree of freedom (DOF) is between and common to the distal ends of the sub-legs, and the proximal end of the link. A joint provides two or more rotational DOFs at the distal end of the link and connects the distal end of the link to one end of the parallel mechanism. Joints in the sub-legs provide DOFs to the sub-legs and connect the proximal ends of the sub-legs to the other end of the parallel mechanism. A degree of actuation (DOA) is provided for each of the sub-legs to control movement of the link.

Abstract: The present application discloses 17? hydroxy steroid dehydrogenase (17? HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17? HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17? HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17? HSD1 and 17? HSD3 that have a spiro-morpholine substituent at C20.

Abstract: Disclosed is a new treatment for reducing amyloid beta (A?), for treating Alzheimer's disease (AD), for improvement of cognitive disorder or learning and memory disorder associated with AD and for the treatment of multiple sclerosis. It was found that a NOD2 agonist could improve phagocytosis of A? across the blood brain barrier, to be scavenged by increased concentration of patrolling monocytes caused by the NOD2 agonist, removing A? from circulation, thereby preventing its eventual deposit. Also disclosed is a composition for such use.